Judo Bio Inc | VCINVEST DATA

Founded

31 Dec 2021

Address

Judo Bio Inc
300 Technology Square
8th Floor
Cambridge, MA 02139
United States

Open Map

Phone

+1 (857) 201-2700

Website

https://judo.bio

Industry

2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Business classification

Bio Therapeutic Drugs

VCID: 9144778

Profile

Corporate information

Official name

Judo Bio Inc

Registration country

United States

Official identities

US CIK 0001955569

Investment activity status

Active investor

Company type

Developer of oligonucleotide medicines delivered to the kidney.

Overview

Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we are using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases.

Funding

Funding rounds

Series A USD 100,000,000

USD 100,000,000 (7 Oct 2024) Change in valuation: unknown

	Profile	Country	Notes
Atlas Venture	Early-stage venture capital firm that creates and invests in biotechnology startup companies in the US.	United States	Initial investment. Led the round.
Alexandria Venture Investments			Initial investment. Round participant.
Digitalis Ventures			Initial investment. Round participant.
Droia Ventures		Belgium	Initial investment. Round participant.
Euclidean Capital			Initial investment. Round participant.
TCG Capital Management LP			Initial investment. Round participant.
The Column Group			Initial investment. Round participant.
YK Bioventures			Initial investment. Round participant.

Sources:

7 Oct 2024

Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney

Industry Dive Inc

Cap Table

Current and past shareholders

	Contacts	Round
Alexandria Venture Investments		Series A
Atlas Venture Early-stage venture capital firm that creates and invests in biotechnology startup companies in the US.		Series A
Digitalis Ventures		Series A
Droia Ventures	+32 2 880 67 30	Series A
Euclidean Capital		Series A
TCG Capital Management LP		Series A
The Column Group		Series A
YK Bioventures		Series A